Last reviewed · How we verify
NCT05286099
The Surveillance of Hepatocellular Carcinoma
trial testing Imaging examination and/or blood test in Hepatocellular Carcinoma in 100 participants. Status unknown.
1 July 2023
Quick facts
| Lead sponsor | Chinese PLA General Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 15 January 2022 |
| Primary completion | 1 July 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 2 locations across China |
Drugs / interventions tested
- Imaging examination and/or blood test
Conditions studied
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Sponsor
Chinese PLA General Hospital
Who can join
Adults 18 to 80, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Early detection of hepatocellular carcinoma is vita to the prognosis of patient. In this study, the occurrence and development of liver cancer were supervised by imaging examination, and the dysplastic nodules will be distinguished from early hepatocellular carcinoma through macro-imaging and micro-pathological features.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Risk stratification and early detection biomarkers for precision HCC screening.
Lee YT, Fujiwara N, Yang JD, Hoshida Y. · · 2023 · cited 90× · PMID 36082510 · DOI 10.1002/hep.32779
Verify or expand the search:
- PubMed search for NCT05286099
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
- NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
- NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
Other Chinese PLA General Hospital trials
Trials by the same sponsor.
- NCT07294755 — The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery · NA · not yet recruiting
- NCT07536607 — Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients · not yet recruiting
- NCT07489157 — Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy · NA · not yet recruiting
- NCT07494981 — Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations · not yet recruiting
- NCT07496008 — Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05286099 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese PLA General Hospital
- Last refreshed: 18 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05286099.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing